Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial Lorusso et al. The Lancet

https://www.thelancet.com/obstetrics-gynaecology-womens-health?dgcid=hubspot_update_feature_lanogwlaunch&utm_campaign=update-lanonc&utm_medium=email&_hsenc=p2ANqtz-8mwwkK5jbaYk2goeGbFu55DyHreOZ51qisVPzeCxJAeKkMo8ht2NgdbAxZlXGkL37lKZ_i-Z5QMqHbnzuvATdeGnrwHg&_hsmi=356617651&utm_content=356548210&utm_source=hs_email